Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- GDTC
- Price
- 2.48
- Stock movement down
- -0.02 (-0.80%)
- Company name
- CytoMed Therapeutics Limited Ordinary Shares
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 28.62M
- Ent value
- 24.75M
- Price/Sales
- 171.96
- Price/Book
- 3.82
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 20.39%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
GDTC does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 171.96 |
| Price to Book | 3.82 |
| EV to Sales | 148.70 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 11.54M |
| EPS (TTM) | -0.32 |
| FCF per share (TTM) | -0.25 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 166.43K |
| Gross profit (TTM) | 2.56K |
| Operating income (TTM) | -4.26M |
| Net income (TTM) | -3.74M |
| EPS (TTM) | -0.32 |
| EPS (1y forward) | -0.15 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 1.54% |
| Operating margin (TTM) | -2559.83% |
| Profit margin (TTM) | -2247.97% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 4.42M |
| Net receivables | 295.19K |
| Total current assets | 5.69M |
| Goodwill | 262.00 |
| Intangible assets | 7.86K |
| Property, plant and equipment | 0.00 |
| Total assets | 8.05M |
| Accounts payable | 33.08K |
| Short/Current long term debt | 316.02K |
| Total current liabilities | 264.10K |
| Total liabilities | 552.53K |
| Shareholder's equity | 7.50M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -2.93M |
| Capital expenditures (TTM) | 490.94K |
| Free cash flow (TTM) | -2.90M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -49.90% |
| Return on Assets | -46.48% |
| Return on Invested Capital | -49.72% |
| Cash Return on Invested Capital | -38.49% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.44 |
| Daily high | 2.56 |
| Daily low | 2.39 |
| Daily Volume | 3K |
| All-time high | 5.64 |
| 1y analyst estimate | 5.00 |
| Beta | - |
| EPS (TTM) | -0.32 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| GDTC | S&P500 | |
| Current price drop from All-time high | -56.03% | -12.89% |
| Highest price drop | -74.29% | -56.47% |
| Date of highest drop | 29 Aug 2024 | 9 Mar 2009 |
| Avg drop from high | -48.43% | -11.07% |
| Avg time to new high | 167 days | 12 days |
| Max time to new high | 442 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
28.62M
Marketcap category
Small-cap
Description
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partner